Expand all sections

Pembrolizumab

Keytruda

Extended indication 1st line non-squamous NSCLC in combination with platinum-pemetrexed.
Therapeutic value No judgement
Total cost 27,025,000.00

Product

Active substance Pembrolizumab
Domain Oncology and Hematology
Main indication Lung cancer
Extended indication 1st line non-squamous NSCLC in combination with platinum-pemetrexed.
Proprietary name Keytruda
Manufacturer MSD
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Expected Registration October 2018
Orphan drug No
Additional remarks Dit is een indicatie-uitbreiding. Aanvraag ingetrokken in november 2017, verwacht: nieuwe indiening.

Therapeutic value

Therapeutic value No judgement
Duration of treatment Not found

Expected patient volume per year

Patient volume

270 - 811

Market share is generally not included unless otherwise stated.
References NKR
Additional remarks NKR 2016: 7728 diagnoses NSCLC, stadium 3 en 4. 35% niet-plaveiselcel. 60% onvangt eerstelijnsbehandeling, waarvan 50% chemotherapie. Dit komt neer op een totaal van 811 patienten. Realistisch volume: marktaandeel delen met nivolumab en atezolizumab: 33,3%; 270 patiënten.

Expected cost per patient per year

Cost 40,000.00 - 60,000.00
References Medicijnkosten.nl
Additional remarks €3.355,96 per injectieflacon van 4 ml, 25 mg/ml.

Potential total cost per year

Total cost

27,025,000.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.